about
Dendritic cell subsets in type 1 diabetes: friend or foe?Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 DiabetesToward beta cell replacement for diabetesRestoring the balance: immunotherapeutic combinations for autoimmune diseaseCombination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice.β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure.Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice.Immune interventions to preserve β cell function in type 1 diabetesAge-related obesity and type 2 diabetes dysregulate neuronal associated genes and proteins in humans.Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model.Back From the Brink: The Uses of Targeting the CXCL10:CXCR3 Axis in Type 1 DiabetesEfficient Presentation of Multiple Endogenous Epitopes to Both CD4+ and CD8+ Diabetogenic T Cells for ToleranceMetabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapiesEnteroviruses, hygiene and type 1 diabetes: toward a preventive vaccine.Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.Intestinal Epithelial Cell Regulation of Adaptive Immune Dysfunction in Human Type 1 DiabetesC1858T Polymorphism of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22): an eligible target for prevention of type 1 diabetes?Metabolically inactive insulin: friend or foe in the prevention of autoimmune diabetes?Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy.Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.
P2860
Q26866500-6D478FB6-EEE2-44E1-86FE-60AC5251E74FQ28071490-B02DC5EB-2CF1-4350-A2A6-4794267B7139Q28083650-33F6564C-3524-498D-865C-5E2B19DBA121Q33555986-505280E2-0BA3-40FE-B45A-BB670CD33CFAQ35665104-EC6A9252-5196-4AA1-B3B1-5624E7EBD0D0Q36019335-E6303AF0-D028-4B11-811E-62577F50F471Q36327212-FC3D4E33-8B98-48EE-B8C7-99B7CE594514Q36520618-FD640918-4AE9-4684-9E1A-0E859FB63BADQ36557442-E9C12EA8-998E-4985-ABBA-98EB67EBBE13Q36741859-82522544-C94F-4F89-89A3-44B3A4BDC73DQ36926382-A325B41F-52FF-47CD-91C7-21E3F836991AQ37717905-F73E9B41-FD31-4F3F-B354-4830E906A446Q38205771-F0C35B19-EC19-4CB7-820F-32113E4BB252Q38272139-1EF08A06-918E-4AAC-BAD2-D75F05D0B5D6Q38904874-448A923F-A3D1-4A0D-8C11-F27EA69D7F35Q39001036-3106B6BD-2FD4-40F6-B2C5-1F3DFA9FF9ADQ39022002-660C96E1-20F6-45C0-9F50-9492497936C0Q45943982-E22F404D-A1C9-41CA-B850-DDB62D962E97Q49444745-3892392B-11D9-4D37-8266-4FA4C45BA83BQ50322302-EEEDB53D-AAD9-42E5-85A5-F00C1315C629
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Trials in type 1 diabetes: Antigen-specific therapies.
@en
type
label
Trials in type 1 diabetes: Antigen-specific therapies.
@en
prefLabel
Trials in type 1 diabetes: Antigen-specific therapies.
@en
P2093
P2860
P1433
P1476
Trials in type 1 diabetes: Antigen-specific therapies.
@en
P2093
Ken T Coppieters
Leonard C Harrison
Matthias G von Herrath
P2860
P304
P356
10.1016/J.CLIM.2013.02.002
P577
2013-02-15T00:00:00Z